WockhardtNSE:WOCKPHARMA -3.03%61 EBITDA Margin % is 30.26% as of Mar. 2026, which is 852% above its 10-year median of 3.18. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 61/100 and a GF Value™ of ₹1,267.12 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Wockhardt ranks better than 67.99% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Wockhardt's EBITDA for the
three
months ended in Mar. 2026 was ₹2,920 Mil. Wockhardt's Revenue for the
three
months ended in Mar. 2026 was ₹9,650 Mil. Therefore, Wockhardt's EBITDA margin for the quarter that ended in Mar. 2026 was 30.26%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Wockhardt EBITDA Margin % Related Terms
Wockhardt EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Wockhardt's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WOCKPHARMA vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Wockhardt's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (NSE:WOCKPHARMA) has a EBITDA Margin % of 30.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wockhardt and its competitors. This is 852% above median its historical median of 3.18. According to the industry distribution chart, Wockhardt ranks #306 out of 956 companies in the Drug Manufacturers industry, placing it in the top 32%.
Is Wockhardt's EBITDA Margin % too high?
Wockhardt's current EBITDA Margin % of 30.26% is 852% above median its 10-year median of 3.18. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Wockhardt's value of 30.26% is 141.8% above this industry median. Based on the distribution chart, Wockhardt ranks #306 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Wockhardt has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #306 out of 956 companies for EBITDA Margin %. This puts Wockhardt in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Wockhardt's value of 30.26% is 141.8% above this benchmark. While the company's 10-year median is 3.18 vs. the industry median of 12.52, Wockhardt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wockhardt's current EBITDA Margin % of 30.26% is 141.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current EBITDA Margin % is 30.26%, which is 852% above median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,267.12, compared to a current price of ₹1,857.40 — trading 46.6% above its estimated fair value. The current EBITDA Margin % is 30.26%, which is 852% above median its 10-year median of 3.18 and 141.8% above the Drug Manufacturers industry median of 12.52. Wockhardt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current EBITDA Margin % is 30.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,857.40 is trading 46.6% above its estimated GF Value™ of ₹1,267.12.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
EBITDA Margin %: 30.26% (852% above median its 10-year median of 3.18)
GF Value™: ₹1,267.12 vs. price of ₹1,857.40 (46.6% above fair value)
Industry Position: 141.8% above the Drug Manufacturers median (#306 of 956)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
61GF Score
Get the complete analysis for NSE:WOCKPHARMA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
